ATB Therapeutics
PrivateLast Round
Series A
Nov 18, 2024
Total Funding Raised
$62.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ATB Therapeutics is a biotechnology company that develops a new class of antibody-based targeted therapies, called atbodies, to treat cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ATB Therapeutics Comparables
Compare ATB Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sutro Biopharma Inc | 72% | |
| Mersana Therapeutics | 69% | |
| Pfizer | 68% |
ATB Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 18, 2024 | ||||
| Seed | Dec 23, 2019 | ||||
| Seed | Jan 1, 2018 |
Key People
Founding team and executive leadership
ATB Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Holding and Investment Company | Series A |
| EQT Life Sciences | Series A |
| Noshaq | Seed |
| Wallonie Entreprendre | Series A |
| V-Bio Ventures | Series A |
| VIVES Partners | Series A |
| Financière Spin-off Luxembourgeoise | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 122% MoM, from 522 to 1.2K.
- Nov 18, 2024
Raised $57M in Series A funding.
ATB Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ATB Therapeutics's valuation, stock price, and market status.
Is ATB Therapeutics a public or private company?
ATB Therapeutics is a private company.
What is the current stock price of ATB Therapeutics?
ATB Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is ATB Therapeutics worth (valuation)?
Valuation information for ATB Therapeutics is not publicly available.
Can I buy ATB Therapeutics stock?
ATB Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ATB Therapeutics's last funding round?
ATB Therapeutics's most recent funding round was Series A on November 18, 2024.
Who are the main investors in ATB Therapeutics?
Key investors in ATB Therapeutics include EQT Life Sciences, Financière Spin-off Luxembourgeoise, ORSA, Fondation Fournier-Majoie.
Will ATB Therapeutics IPO soon?
No public IPO plans have been announced for ATB Therapeutics.
How can I track ATB Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ATB Therapeutics's secondary market activity and sign up for updates.